CervoMed Inc., formerly Diffusion Pharmaceuticals Inc., is a clinical-stage biotechnology company. The Company is advancing central nervous system (CNS)-focused therapeutics to treat patients with a range of degenerative diseases of the brain. Its lead product candidate, neflamapimod, is an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies (DLB), early Alzheimer’s disease and stroke recovery. The Company’s neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and other neurological disorders. Its Neflamapimod is evaluated in a Phase IIb study in patients with DLB. The Company's wholly owned subsidiary is EIP Pharma Inc.